DK2044199T3 - Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi - Google Patents

Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi

Info

Publication number
DK2044199T3
DK2044199T3 DK07810511.1T DK07810511T DK2044199T3 DK 2044199 T3 DK2044199 T3 DK 2044199T3 DK 07810511 T DK07810511 T DK 07810511T DK 2044199 T3 DK2044199 T3 DK 2044199T3
Authority
DK
Denmark
Prior art keywords
serca2a
anterograde
adeno
extended
gene therapy
Prior art date
Application number
DK07810511.1T
Other languages
Danish (da)
English (en)
Inventor
Krisztina Maria Zsebo
Original Assignee
Celladon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celladon Corp filed Critical Celladon Corp
Application granted granted Critical
Publication of DK2044199T3 publication Critical patent/DK2044199T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK07810511.1T 2006-07-25 2007-07-16 Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi DK2044199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83332406P 2006-07-25 2006-07-25
PCT/US2007/016129 WO2008013692A2 (en) 2006-07-25 2007-07-16 Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy

Publications (1)

Publication Number Publication Date
DK2044199T3 true DK2044199T3 (da) 2013-02-11

Family

ID=38581949

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07810511.1T DK2044199T3 (da) 2006-07-25 2007-07-16 Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi

Country Status (13)

Country Link
US (2) US20080076730A1 (cg-RX-API-DMAC7.html)
EP (2) EP2044199B1 (cg-RX-API-DMAC7.html)
JP (2) JP5623740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090035711A (cg-RX-API-DMAC7.html)
CN (1) CN101495627A (cg-RX-API-DMAC7.html)
AU (1) AU2007277392A1 (cg-RX-API-DMAC7.html)
CA (1) CA2658628A1 (cg-RX-API-DMAC7.html)
DK (1) DK2044199T3 (cg-RX-API-DMAC7.html)
ES (1) ES2398593T3 (cg-RX-API-DMAC7.html)
GB (1) GB2437893A (cg-RX-API-DMAC7.html)
IL (1) IL196541A (cg-RX-API-DMAC7.html)
PL (1) PL2044199T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008013692A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
PH12012501579A1 (en) * 2010-01-05 2012-10-22 Michael Aaron Vertical axis variable geometry wind energy collection system
US11583662B2 (en) 2016-04-18 2023-02-21 Sardocor Corp. Methods and compositions for consistent intracoronary administration of a biologic
KR20240093919A (ko) * 2017-04-14 2024-06-24 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
CN117241855A (zh) * 2021-02-22 2023-12-15 迪纳柯公司 肝脏的局部区域灌注

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) * 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US5773289A (en) * 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
EP1053025A2 (en) * 1998-02-11 2000-11-22 The Regents of the University of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1324780A4 (en) * 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
CA2422078C (en) * 2000-09-11 2011-08-09 The Regents Of The University Of California High efficiency cardiac gene transfer
CN103589692B (zh) * 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
WO2005014835A1 (en) * 2003-07-17 2005-02-17 Bayerische Julius-Maximilians- Universität Würzburg Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis
US7291604B2 (en) * 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
EP1691609A4 (en) * 2003-12-11 2006-11-29 Mirus Bio Corp RELEASE OF VIRUS VECTORS ANEXTRAVASAL PARENCHYM CELLS
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CA2579519A1 (en) * 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
WO2006089340A2 (en) * 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2244740A1 (en) * 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium

Also Published As

Publication number Publication date
WO2008013692A2 (en) 2008-01-31
JP5623740B2 (ja) 2014-11-12
CA2658628A1 (en) 2008-01-31
CN101495627A (zh) 2009-07-29
US20170252462A1 (en) 2017-09-07
EP2460879A1 (en) 2012-06-06
GB0716413D0 (en) 2007-10-03
EP2044199A2 (en) 2009-04-08
WO2008013692A3 (en) 2008-05-02
IL196541A0 (en) 2009-11-18
JP2009544698A (ja) 2009-12-17
GB2437893A (en) 2007-11-07
AU2007277392A1 (en) 2008-01-31
US20080076730A1 (en) 2008-03-27
ES2398593T3 (es) 2013-03-20
IL196541A (en) 2012-12-31
EP2044199B1 (en) 2012-11-14
KR20090035711A (ko) 2009-04-10
JP2014218509A (ja) 2014-11-20
PL2044199T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
NO2023029I1 (no) Etranacogene dezaparvovec (an adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX gene)
ATE528007T1 (de) Lagerstabile infusionslösung von dihydropteridinonen
DK2527471T3 (da) Diagnosticering af cancer ved anvendelse af genomsekvensering
HUE061060T2 (hu) Replikáció-defektív arenavírus vektorok
EP2076162A4 (en) DISHWASHER WITH ADJUSTABLE BASKET / ADJUSTABLE BASKETS
PL3150586T3 (pl) Modulatory farmakokinetycznych właściwości środków terapeutycznych
DK2054428T3 (da) Udvikling af bestanddele til denque-virus-vaccine
EP2131390A4 (en) PLASMA PROCESSOR
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
EP2176420A4 (en) DERIVED FROM VIRUS ANTIMICROBIAL PEPTIDES
DK2222315T3 (da) Stabiliserede faktor-ix-formuleringer indeholdende trehalose
HUE036071T2 (hu) Macitentánt tartalmazó terápiás készítmények
EP2349415A4 (en) CANNULA HOUSING FOR SIMPLE MEDICINAL INJECTION
BRPI0811016A2 (pt) Proteína li truncada do papiloma vírus humano tipo 16
EP1859166A4 (en) MAGNETIC PUMP WITHOUT CONSOLE
EP2326327A4 (en) ANALOGS OF INDOL-3-CARBINOL AND ITS USE AS AGENTS AGAINST INFLAMMATION
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1733039T3 (da) Forbedret bakteriel værtscelle til direkte ekspression af peptider
DE602005027253D1 (de) Herbizidresistenz verleihende gene
EP1955719A4 (en) OPPOSITION AGAINST INFECTIONS WITH FLUTING VIRUS
PL2044199T3 (pl) Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
DK2178903T3 (da) Optimeret denguevirus-adgangsinhiberede peptid (DN81)
DE602008005536D1 (de) Herstellung von MnB12H12
PL1901783T3 (pl) Kwas gentyzynowy do stabilizowania środków radiofarmaceutycznych 123-i
EP1978260A4 (en) ZENTRIFUGALABFLUSSPUMPE